<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1345">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05143645</url>
  </required_header>
  <id_info>
    <org_study_id>K 2019-9605</org_study_id>
    <nct_id>NCT05143645</nct_id>
  </id_info>
  <brief_title>A New Protocol for Continuous Vancomycin Infusion Dosing.</brief_title>
  <acronym>CVIP</acronym>
  <official_title>Evaluation of a New Clinical Protocol for Dose Selection of Vancomycin for Continuous Infusion in ICU Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study prospectively collect data on chosen dosing, renal function,&#xD;
      measured plasma concentrations and adherence to the recommended clinical protocl for ICU&#xD;
      patients treated with continuous vancomycin infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2013</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time (days) from start of treatment to first measurement of a plasma vancomycin concentration between 20 and 25 mg/mL</measure>
    <time_frame>Until the end of treatment or discharge from unit</time_frame>
    <description>The title is a full description.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between time to intended concentration (15-20 mg/L) and adherence to the dosing protocol (% complete adherence).</measure>
    <time_frame>Until the end of treatment or discharge from unit</time_frame>
    <description>For each patient the actually administired dose of vancomycin will be compared to the recommendation in the dosing protocol. The time to the intended concentration will be compared between patients with 100% adherence to the recommendations and for patients with dosing not following the recommendations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of the total treatment duration with the intended plasma concentration 15-20 mg/L.</measure>
    <time_frame>Until the end of treatment or discharge from unit</time_frame>
    <description>The title is a full description.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between Percentage of the total treatment duration with the intended plasma concentration (15-20 mg/L) and adherence to the dosing protocol.</measure>
    <time_frame>Until the end of treatment or discharge from unit</time_frame>
    <description>The title in combination with the description of outcome 2 is a sufficient description.</description>
  </secondary_outcome>
  <enrollment type="Actual">101</enrollment>
  <condition>Sepsis</condition>
  <condition>Vancomycin Treatment</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasma vancoymcin measurements</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ICU patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Start of continuous vancomycin infusion during the course of intensive care and at least&#xD;
        one measurement of plasma concentration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vancomycin treatment within 96 h before admission to the unit.&#xD;
&#xD;
          -  Vancomycin treatment started with intermittent bolus infusions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska University Hospital Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Johan Petersson</investigator_full_name>
    <investigator_title>Senior ICU Consultant</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

